NASDAQ:BIAFW bioAffinity Technologies (BIAFW) Stock Price, News & Analysis → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Free BIAFW Stock Alerts $0.77 +0.07 (+9.34%) (As of 12:54 PM ET) Add Compare Share Share Today's Range$0.77▼$0.7750-Day Range$0.06▼$0.7652-Week Range$0.05▼$0.86Volume365 shsAverage Volume5,384 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get bioAffinity Technologies alerts: Email Address Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About bioAffinity Technologies Stock (NASDAQ:BIAFW)bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.Read More BIAFW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIAFW Stock News HeadlinesMarch 5, 2024 | finance.yahoo.combioAffinity Technologies Reports Accelerating Sales Growth of CyPath® LungDecember 5, 2023 | finance.yahoo.combioAffinity Technologies Appoints Jamie Platt, Ph.D., to its Board of DirectorsMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… November 28, 2023 | finance.yahoo.combioAffinity Technologies VP David Elzi, Ph.D., Named to American Society for Cell Biology PostNovember 16, 2023 | msn.combioAffinity Technologies files for a $25M mixed shelf offeringOctober 10, 2023 | finance.yahoo.combioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth ConferenceSeptember 19, 2023 | finance.yahoo.combioAffinity Technologies Acquires Laboratory Assets of Precision Pathology ServicesSeptember 15, 2023 | wsj.combioAffinity Technologies Inc. WtMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… August 14, 2023 | finance.yahoo.combioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business UpdateJuly 12, 2023 | finance.yahoo.comAMA Issues CPT Code for bioAffinity Technologies’ CyPath® Lung Test for Early-Stage Lung CancerJune 15, 2023 | finance.yahoo.combioAffinity Technologies Presents Research Findings at UMass RNA Therapeutics SymposiumMay 22, 2023 | finance.yahoo.combioAffinity Technologies Presents Research Findings at CYTO 2023April 7, 2023 | nasdaq.combioAffinity Technologies, Inc. Rings the Nasdaq Stock Market Closing BellApril 7, 2023 | nasdaq.combioAffinity Technologies, Inc. Rings the Closing BellApril 4, 2023 | bizjournals.comAfter launching IPO, promising SA biotech still chasing profitabilityMarch 24, 2023 | finance.yahoo.combioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023February 13, 2023 | finance.yahoo.combioAffinity Technologies Appoints Julie Anne Overton Director of Corporate CommunicationsJanuary 4, 2023 | marketwatch.comBioAffinity Technologies Shares Rise 8% After Getting Notice to Allow U.S. PatentDecember 1, 2022 | finance.yahoo.combioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO MeetingNovember 14, 2022 | finance.yahoo.combioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 10, 2022 | finance.yahoo.combioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company’s Scientific and Medical Advisory BoardOctober 25, 2022 | finance.yahoo.combioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and AustraliaOctober 12, 2022 | finance.yahoo.combioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST ConferenceSeptember 28, 2022 | finance.yahoo.combioAffinity Technologies Receives Additional $7.7M from Exercise of Warrants, Total Capital from Public Offering Increases to Approximately $15.6MSeptember 27, 2022 | nasdaq.combioAffinity Technologies, Inc. Warrant (BIAFW)September 14, 2022 | finance.yahoo.combioAffinity Technologies Publishes Peer-Reviewed Results of High-Throughput Flow Cytometry Use for Evaluating Lung Health in PLOS ONESee More Headlines Receive BIAFW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bioAffinity Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolNASDAQ:BIAFW CUSIPN/A CIK1712762 Webwww.bioaffinitytech.com Phone210 698 5334FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$321,489.00 Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Steven Girgenti (Age 78)Founder & Executive Chairman of the Board Comp: $93.33kMs. Maria Zannes J.D. (Age 68)Founder, President, CEO & Director Comp: $260.81kDr. Vivienne I. Rebel M.D. (Age 59)Ph.D., Executive VP and Chief Medical & Science Officer Comp: $238.39kMr. Michael Dougherty CPA (Age 46)M.B.A., VP & CFO Mr. Xavier T. Reveles M.S. (Age 55)Chief Operating Officer Mr. Timothy P. Zannes J.D. (Age 71)Executive VP, Secretary & General Counsel Ms. Julie Anne OvertonDirector of CommunicationsMr. Dallas J. ColemanNational Director of SalesDr. William Bauta Ph.D.Senior Vice President of TherapeuticsMore ExecutivesKey CompetitorsLumiraDxNASDAQ:LMDXWPrenetics GlobalNASDAQ:PRENWSeqLLNASDAQ:SQLLWStar EquityNASDAQ:STRRP180 Life SciencesNASDAQ:ATNFWView All Competitors BIAFW Stock Analysis - Frequently Asked Questions How have BIAFW shares performed in 2024? bioAffinity Technologies' stock was trading at $0.0860 at the beginning of the year. Since then, BIAFW stock has increased by 714.0% and is now trading at $0.70. View the best growth stocks for 2024 here. Are investors shorting bioAffinity Technologies? bioAffinity Technologies saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 200 shares, a decline of 92.6% from the February 29th total of 2,700 shares. Based on an average daily volume of 2,800 shares, the days-to-cover ratio is currently 0.1 days. View bioAffinity Technologies' Short Interest. How do I buy shares of bioAffinity Technologies? Shares of BIAFW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BIAFW) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bioAffinity Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.